OTCPK:NEPTF - Post by User
Post by
gwrbion Oct 15, 2009 8:30pm
411 Views
Post# 16392345
Q2 Results
Q2 Results
I'm with Riskfetish - the SP is definitely going up. A lot of this lingering around $2 on crappy volume is based on the uncertainty around short-term challenges (i.e. Schiff/production increases/lack of info on Bayer/cash burn rate, etc.).
The next few weeks should mark the bottom (on the way to $5-$7).
But, management continues to bungle the job.
As for the release:
"Management change" is singular, yet two executives left. Normally, such "change" would be accompanied by replacements (to create some excitement). But, we can only assume - there are no replacements yet. Also, why would anyone leave shortly after the Bayer announcement. It leads to lots of questions. And points at continued fraction within the management ranks for anyone whose last name is not Harland. This is bush. Having said that, Rinow seemed pretty weak to me anyways.
Given the one time hit (which apparently impacted 2 quarters), why wouldn't they release some future guidance of what their capability is now that production is 50% higher? This would quickly push the negativity of the one time hit into the rear view mirror. Further, the Laval plant capacity (even as expanded) will be an impediment to this company's real global growth profile. So where is the commentary on production partners world wide??
And I can't believe no commentary on the positives - Bayer/Valensa/Weider/sales replacement for Schiff,etc... It almost appears they want to artificially keep the SP down.
And I can't stand reading about the operating loss breakdown between Neptune and Acasti et al. This is too small a company at the present time to be wasting valuable management time detailing those micro-gyrations. Why don't they just admit the Acasti spin out stuff is a failure from last summer, and that the spin out/partner stuff is probably on hold for the foreseeable future until the venture capitalists return (although all the big pharmas are scared silly about replacing their product pipelines).
Management continues to p___ me off, and I will only increase my excitement once the Bayer commercialization deal is finalized and announced and/or the elder Harland moves aside and they bring in an ambitious, pharma shooter to get this sleepy little company going.
I can't believe Hughie hasn't blown a gasket by now.